Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma

Archives of Dermatology

Volumn 148, Issue 3, 2012, Pages 363-366

  Alloo, Allireza ^a   Garibyan, Lilit ^a   LeBoeuf, Nicole ^a,b   Lin, George ^a   Werchniak, Andrew ^a,b   Hodi, F Stephen ^b   Flaherty, Keith T ^c   Lawrence, Donald P ^c   Lin, Jennifer Y ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; VEMURAFENIB;

AGED; ANEMIA; APPLICATION SITE ERYTHEMA; ARTICLE; BRAIN METASTASIS; CANCER STAGING; CASE REPORT; CLINICAL TRIAL; DISEASE ASSOCIATION; HISTOPATHOLOGY; HUMAN; KERATOACANTHOMA; MALE; MELANOMA; PHOTODYNAMIC THERAPY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SKIN BIOPSY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84863376176     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2011.3080     Document Type: Article

References (13)

1. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954. (Pubitemid 34716871)
2. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809-819.
3. Chapman PB, Hauschild A, Robert C, et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
4. Karaa A, Khachemoune A. Keratoacanthoma: a tumor in search of a classification. Int J Dermatol. 2007;46(7):671-678. (Pubitemid 47046182)
5. Pattee SF, Silvis NG. Keratoacanthoma developing in sites of previous trauma: a report of two cases and review of the literature. J Am Acad Dermatol. 2003;48(2)(suppl):S35-S38. (Pubitemid 36231886)
6. Braathen LR, Szeimies RM, Basset-Seguin N, et al International Society for Photodynamic Therapy in Dermatology. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. J AmAcad Dermatol. 2007;56(1):125-143. (Pubitemid 44969292)
7. Calzavara-Pinton PG, Venturini M, Sala R, et al. Methylaminolaevulinate- based photodynamic therapy of Bowen's disease and squamous cell carcinoma. Br J Dermatol. 2008;159(1):137-144. (Pubitemid 351874478)
8. Morton C, Horn M, Leman J, et al. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or fluorouracil for treatment of squamous cell carcinoma in situ: results of a multicenter randomized trial. Arch Dermatol. 2006;142(6):729-735.
9. Radakovic-Fijan S, Hönigsmann H, Tanew A. Efficacy of topical photodynamic therapy of a giant keratoacanthoma demonstrated by partial irradiation. Br J Dermatol. 1999;141(5):936-938.
10. Yeon JH, Jung JY, Choi JW, et al. Keratoacanthoma aggravated after photodynamic therapy. J Dermatol. 2010;37(8):765-766.
11. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell. 2010;140(2):209-221.
12. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010; 464(7287):427-430.
13. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010;464(7287):431-435.